Overview

Study of AP23573/MK-8669 (Ridaforolimus), A Mammalian Target of Rapamycin (mTOR) Inhibitor, in Participants With Advanced Sarcoma (MK-8669-018 AM1)(COMPLETED)

Status:
Completed

Trial end date:
2008-11-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to assess the efficacy of ridaforolimus when administered once daily for 5 consecutive days (QDx5) every two weeks in participants with advanced sarcoma.

Phase:

Phase 2

Details

Lead Sponsor:

Merck Sharp & Dohme Corp.

Collaborator:

Ariad Pharmaceuticals

Treatments:

Sirolimus